Nadecnemab Biosimilar Monoclonal Antibody (GFRA3) for Research

Cat No.: GMP-Bios-ab-361

Pre-Made Nadecnemab biosimilar, Whole mAb, Anti-GFRA3 Antibody: Anti-GDNFR3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.



Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-361-1mg 1mg 618

Size: 1mg | 10mg | 100mg



Product Details

Products Name (INN Index) Pre-Made Nadecnemab biosimilar, Whole mAb, Anti-GFRA3 Antibody: Anti-GDNFR3 therapeutic antibody
INN Name Nadecnemab
TargetGFRA3
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2020
Year Recommendedna
CompaniesRegeneron Pharmaceuticals
Conditions Approvedna
Conditions ActiveOsteoarthritis;Pain chronic
Conditions Discontinuedna
Development Techna



About target - GFRA3

1. Protein GDNF family receptor alpha-3

2. Gene GFRA3

3. Organism Homo sapiens (Human)

Function
Receptor for the glial cell line-derived neurotrophic factor, ARTN (artemin). Mediates the artemin-induced autophosphorylation and activation of the RET receptor tyrosine kinase.